Clinical Colorectal Cancer NOVEMBER 15, 2006

Capecitabine versus Bolus 5-Fluorouracil/Leucovorin as Adjuvant Therapy for Colon Cancer (The X-ACT Study)

Christopher Twelves, James Cassidy, Werner Scheithauer, et al.

Bottom Line

The X-ACT trial established that oral capecitabine is a non-inferior and better-tolerated alternative to intravenous bolus 5-fluorouracil/leucovorin (Mayo Clinic regimen) as adjuvant treatment for patients with stage III colon cancer.

Key Findings

1. The primary endpoint of non-inferiority for disease-free survival (DFS) was met; capecitabine was at least equivalent to 5-FU/LV, with a hazard ratio (HR) for DFS of 0.88 (95% CI 0.77–1.01) at a median follow-up of 6.9 years.

2. Capecitabine demonstrated a trend toward superior overall survival compared to 5-FU/LV, with an HR of 0.86 (95% CI 0.74–1.01).

3. Capecitabine was associated with a significantly superior safety profile regarding systemic toxicities, showing fewer grade 3/4 adverse events (e.g., neutropenia, stomatitis, and diarrhea) compared to the 5-FU/LV control group (P < 0.001).

4. Hand-foot syndrome and hyperbilirubinemia were significantly more frequent in the capecitabine group (P < 0.001) compared to the bolus 5-FU/LV regimen.

Study Design

Design

RCT

Open-Label

Sample

1,987

Patients

Duration

6.9 yr

Median

Setting

Multicenter, global

Population Patients with resected stage III (Dukes' C) colon cancer

Intervention Oral capecitabine (1,250 mg/m2 twice daily on days 1–14, every 3 weeks) for 24 weeks

Comparator Intravenous bolus 5-fluorouracil (425 mg/m2) and leucovorin (20 mg/m2) (Mayo Clinic regimen) for 24 weeks

Outcome Disease-free survival (DFS)

Study Limitations

• The study compared capecitabine against the bolus Mayo Clinic 5-FU/LV regimen, which is no longer the standard of care as it has been largely superseded by combination regimens such as FOLFOX or CAPOX for stage III colon cancer.

• The trial was open-label, which may have introduced assessment bias, particularly regarding the reporting of toxicities.

• The trial was designed for non-inferiority rather than superiority, limiting the statistical power to definitively prove the superiority of capecitabine.

Clinical Significance

The X-ACT trial provided the evidence base to support the use of oral capecitabine as a convenient, effective, and less toxic alternative to traditional bolus intravenous 5-FU regimens for the adjuvant treatment of colon cancer, facilitating outpatient care.

Historical Context

Prior to this trial, bolus 5-FU/leucovorin (specifically the Mayo Clinic regimen) was the long-standing standard of care for adjuvant colon cancer. X-ACT was instrumental in validating an oral fluoropyrimidine monotherapy option, shifting clinical practice toward more patient-friendly, home-based chemotherapy administration.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the metabolic activation pathway of capecitabine provide a theoretical advantage in tumor selectivity compared to systemic bolus 5-fluorouracil?

Key Response

Capecitabine is an oral prodrug that undergoes a three-step enzymatic conversion to 5-FU. The final step is mediated by thymidine phosphorylase (TP), an enzyme that is often expressed at significantly higher levels in malignant cells compared to healthy tissue, theoretically concentrating the active drug within the tumor and reducing systemic toxicity.

Resident

In the context of the X-ACT trial results, for which specific patient population would capecitabine monotherapy be the most appropriate adjuvant choice over modern oxaliplatin-containing regimens?

Key Response

While oxaliplatin-based combinations (FOLFOX or CAPOX) are the standard for fit stage III patients, capecitabine monotherapy is the evidence-based alternative for patients who are older, have significant comorbidities, or have pre-existing peripheral neuropathy where the added toxicity of oxaliplatin outweighs the incremental survival benefit.

Fellow

The X-ACT trial established non-inferiority of capecitabine to bolus 5-FU/LV. How do the toxicity profiles specifically differ between these two regimens, and how does this impact the interpretation of 'non-inferiority' in a curative adjuvant setting?

Key Response

Capecitabine significantly reduced the incidence of grade 3/4 diarrhea and stomatitis compared to the Mayo Clinic bolus regimen, but it significantly increased the incidence of hand-foot syndrome (palmar-plantar erythrodysesthesia). In a non-inferiority trial, 'clinical benefit' is often a composite of efficacy, safety, and quality of life; the improved safety and convenience of oral dosing justified its adoption despite similar survival outcomes.

Attending

Given that the X-ACT trial used the Mayo Clinic bolus 5-FU/LV regimen as the control, how would the trial's conclusions regarding safety and efficacy likely change if it were compared against an infusional 5-FU regimen (e.g., de Gramont)?

Key Response

Infusional 5-FU is known to be less toxic and potentially more efficacious than bolus delivery. While capecitabine's efficacy would likely remain non-inferior, the 'superior' safety profile observed in X-ACT (specifically regarding neutropenia and GI toxicity) might have been less pronounced or non-existent if compared to a more modern infusional control.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The X-ACT study utilized a non-inferiority margin based on a hazard ratio (HR) of 1.20 for disease-free survival. What are the statistical risks of utilizing such a margin in an adjuvant trial, and how does this margin influence the sample size requirements compared to a standard superiority trial?

Key Response

A non-inferiority margin of 1.20 means the researchers are willing to accept that the new drug could be up to 20% worse than the standard while still being deemed 'non-inferior.' This requires a much larger sample size to ensure the upper bound of the 95% confidence interval does not cross 1.20, providing high statistical confidence that the therapeutic effect is preserved.

Journal Editor

As a reviewer, how would you evaluate the external validity of the X-ACT trial results considering the high level of patient monitoring required for an oral chemotherapy trial versus the 'real-world' risk of non-adherence?

Key Response

A primary threat to the validity of oral chemotherapy trials is patient compliance. In a clinical trial setting, adherence is strictly monitored. In real-world practice, poor adherence to the twice-daily capecitabine schedule could result in lower dose intensity and poorer outcomes compared to the observed trial results, a factor that editors must weigh when assessing the generalizability of 'non-inferiority'.

Guideline Committee

Based on the X-ACT and subsequent IDEA collaboration data, how should guidelines reconcile the duration of adjuvant therapy when using capecitabine monotherapy versus combination CAPOX?

Key Response

While the X-ACT trial utilized a 6-month (30-week) course of capecitabine, the IDEA collaboration suggested that for low-risk stage III colon cancer (T1-3, N1), 3 months of CAPOX is non-inferior to 6 months. However, for monotherapy, the 6-month duration established by X-ACT remains the standard (Category 1 in NCCN) because there is insufficient data to support shortening the duration of single-agent fluoropyrimidines.

Clinical Landscape

Noteworthy Related Trials

2004

MOSAIC Trial

n = 2,246 · NEJM

Tested

FOLFOX4 (5-FU, leucovorin, and oxaliplatin)

Population

Patients with stage III colon cancer

Comparator

LV5FU2 (5-fluorouracil and leucovorin)

Endpoint

Disease-free survival

Key result: The addition of oxaliplatin to 5-FU and leucovorin significantly improved disease-free survival compared to 5-FU/leucovorin alone.

2007

NSABP C-06 Trial

n = 2,079 · JCO

Tested

Oral uracil/tegafur plus leucovorin

Population

Patients with stage II or III colon cancer

Comparator

Bolus 5-fluorouracil plus leucovorin (Roswell Park regimen)

Endpoint

Disease-free survival

Key result: Oral UFT/LV was found to be at least as effective as bolus 5-FU/LV in terms of disease-free and overall survival.

2007

QUASAR Trial

n = 3,239 · Lancet

Tested

5-fluorouracil and folinic acid

Population

Patients with stage II colon cancer

Comparator

Observation

Endpoint

Recurrence-free survival and overall survival

Key result: Adjuvant chemotherapy with 5-FU/FA resulted in a modest but significant reduction in the risk of recurrence and mortality.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis